Literature DB >> 8509215

Increasing incidence of both major histological types of esophageal carcinomas among men in Sweden.

L E Hansson1, P Sparén, O Nyrén.   

Abstract

Although a rare tumor form, there is evidence that the incidence of esophageal adenocarcinomas is increasing in Western Europe and the US. The aim of this nationwide population-based study was to describe the secular trends in the incidence rates of adenocarcinoma and squamous-cell carcinoma of the esophagus over a 28-year period from 1960 to 1987. The Swedish Cancer Registry, complete to more than 95%, was used to identify the cases. The percentage verified by histology rose from 89% to 98%. The age-standardized incidence rate of adenocarcinoma increased in males from 0.5 per 10(5) in 1960-63 to 1.1 per 10(5) in 1984-87, corresponding to an average annual increase of 1.5%. In females the incidence remained stable around 0.2 per 10(5). The age-standardized incidence rate of squamous-cell carcinoma in males increased from 2.9 to 4.0 per 10(5), corresponding to an average annual increase of 1.0%. In females the rate decreased from 1.4 to 1.2 per 10(5), corresponding to an annual average decrease of 0.5%. The male/female ratio was 4.6 for adenocarcinoma and 2.7 for squamous-cell carcinoma of the esophagus. Since the incidence rates of squamous-cell carcinoma of the esophagus and of adenocarcinoma seem to be rising, there is a great need for well-planned analytical epidemiological studies of these tumor locations, taking the histological type into consideration.

Entities:  

Mesh:

Year:  1993        PMID: 8509215     DOI: 10.1002/ijc.2910540309

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  32 in total

Review 1.  Management of upper gastrointestinal cancers.

Authors:  A Melville; E Morris; D Forman; A Eastwood
Journal:  Qual Health Care       Date:  2001-03

Review 2.  Molecular biology of Barrett's adenocarcinoma.

Authors:  B P Wijnhoven; H W Tilanus; W N Dinjens
Journal:  Ann Surg       Date:  2001-03       Impact factor: 12.969

3.  Correlation between endoscopic macroscopic type and invasion depth for early esophagogastric junction adenocarcinomas.

Authors:  Ichiro Oda; Seiichiro Abe; Chika Kusano; Haruhisa Suzuki; Satoru Nonaka; Shigetaka Yoshinaga; Hirokazu Taniguchi; Tadakazu Shimoda; Takuji Gotoda
Journal:  Gastric Cancer       Date:  2011-01-28       Impact factor: 7.370

4.  Should we continue oesophageal surgery in a district general hospital? A review of 200 consecutive cases.

Authors:  T C B Dehn; Iain Paterson; David Hunter; David Rae
Journal:  Ann R Coll Surg Engl       Date:  2002-07       Impact factor: 1.891

Review 5.  Adenocarcinoma of the esophagogastric junction: incidence, characteristics, and treatment strategies.

Authors:  Shinichi Hasegawa; Takaki Yoshikawa
Journal:  Gastric Cancer       Date:  2010-07-03       Impact factor: 7.370

Review 6.  Adenocarcinoma of oesophagus: what exactly is the size of the problem and who is at risk?

Authors:  J Lagergren
Journal:  Gut       Date:  2005-03       Impact factor: 23.059

7.  Gastric acid suppression and risk of oesophageal and gastric adenocarcinoma: a nested case control study in the UK.

Authors:  L A García Rodríguez; J Lagergren; M Lindblad
Journal:  Gut       Date:  2006-06-19       Impact factor: 23.059

8.  Detection of adenocarcinoma in Barrett's oesophagus by means of laser induced fluorescence.

Authors:  C S von Holstein; A M Nilsson; S Andersson-Engels; R Willén; B Walther; K Svanberg
Journal:  Gut       Date:  1996-11       Impact factor: 23.059

9.  Risk of oesophageal cancer in Barrett's oesophagus and gastro-oesophageal reflux.

Authors:  M Solaymani-Dodaran; R F A Logan; J West; T Card; C Coupland
Journal:  Gut       Date:  2004-08       Impact factor: 23.059

10.  Mortality in Barrett's oesophagus: results from a population based study.

Authors:  L A Anderson; L J Murray; S J Murphy; D A Fitzpatrick; B T Johnston; R G P Watson; P McCarron; A T Gavin
Journal:  Gut       Date:  2003-08       Impact factor: 23.059

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.